115010-10-1

Basic information

• Product Name: BENZO[1,3]DIOXOLE-5-SULFONYL CHLORIDE
• Synonyms: OTAVA-BB BB7020430867;BENZO[1,3]DIOXOLE-5-SULFONYL CHLORIDE;1,3-BENZODIOXOLE-5-SULFONYL CHLORIDE;1,3-BENZODIOXOLE-5-SULPHONYL CHLORIDE;1,3-Benzodioxole-5-sulphonyl chloride 97%;benzo[d][1,3]dioxole-5-sulfonyl chloride;(2-phenyl-2H-1,3-dioxol-4-yl)(sulfonyl)chloranuide;1,3-Benzodioxole-5-sulphonyl chloride 95+%
• CAS NO: 115010-10-1
• Molecular Formula: C₇H₅ClO₄S
• Molecular Weight: 220.63
• Mol File: 115010-10-1.mol

Chemical Properties

• Melting Point: 46-49
• Boiling Point: 326.5 °C at 760 mmHg
• Flash Point: >110℃
• Appearance: /
• Density: 1.607 g/cm³
• Vapor Pressure: 0.000409mmHg at 25°C
• Refractive Index: 1.592
• Storage Temp.: 2-8°C
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: BENZO[1,3]DIOXOLE-5-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZO[1,3]DIOXOLE-5-SULFONYL CHLORIDE(115010-10-1)
• EPA Substance Registry System: BENZO[1,3]DIOXOLE-5-SULFONYL CHLORIDE(115010-10-1)

Safety Data

• Hazard Codes: C,Xi
• Statements: 14-34-36
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3261 8 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 115010-10-1(Hazardous Substances Data)

Usage

Uses

1,3-Benzodioxole-5-sulfonyl chloride is used as an organic chemical synthesis intermediate.

InChI:InChI=1/C7H5ClO4S/c8-13(9,10)5-1-2-6-7(3-5)12-4-11-6/h1-3H,4H2

Upstream product

• 69849-38-3 trimethyl(3,4-methylenedioxyphenyl)stannane 
• 274-09-9 Methylenedioxybenzene 
• 143018-62-6 Potassium; benzo[1,3]dioxole-5-sulfonate 
• 107-06-2 1,2-dichloro-ethane 
• 94839-07-3 3,4-(methylenedioxy)-benzeneboronic acid 
• 79-37-8 oxalyl dichloride 
• 271-97-6 benzodioxole 
• 75-34-3 1,1-dichloroethane 

Downstream Products

• 288291-36-1 {(1S,2R)-3-[(Benzo[1,3]dioxole-5-sulfonyl)-(4-cyano-2,2-dimethyl-butyl)-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid tert-butyl ester 
• 180031-05-4 methyl 3-(benzo[1,3]dioxol-5-sulphonylamino)-4-(2-methoxy-phenoxy)-5-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-benzoate 
• 174303-68-5 1-[N-[(1,3-benzodioxol-5-yl) sulfonyl]-N-(2-methylpropyl)amino]-3(S)-[N,N-bis(phenylmethyl)amino]-4-phenyl-2(R)-butanol 
• 1203493-79-1 1-(benzo[d][1,3]dioxol-5-ylsulfonyl)-4-(2,6-difluorophenylsulfonyl)piperazine 
• 1447963-69-0 N-[2-(3,4-dimethoxyphenyl)ethyl]-1,3-benzodioxole-5-sulfonamide 
• 956467-56-4 (2S,5S)-1-(1,3-benzodioxol-5-ylsulfonyl)-4-{[3,4-bis(methyloxy)phenyl]sulfonyl}-2,5-dimethylpiperazine 
• 160233-05-6 N-[(1S,2R)-3-[[(benzo-[1,3]-dioxole-5-sulfonyl)](isobutyl)amino]-1-benzyl-2-hydroxypropyl]carbamic acid tert-butyl ester 
• 313679-53-7 t-butyl-N((1S,2R)-1-(4-benzyloxy-benzyl)-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl]-amino-2-hydroxypropyl)-carbamate 

Relevant articles and documents

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

Piperazine adenosine monophosphate activated protein kinase (AMPK) agonist and medical application thereof

The invention discloses a piperazine compound with AMPK agonist activity, and a preparation method and medical application of the piperazine compound. The piperazine compound is a compound shown as aformula (I) (please see the specifications for the formula), and a pharmaceutically acceptable salt or ester or a prodrug or N-oxide or solvate thereof. The compound can be used for preparing drugs for preventing or treating AMPK-mediated diseases.

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Synthesis of aryl sulfonamides via palladium-catalyzed chlorosulfonylation of arylboronic acids

A palladium-catalyzed method for the preparation of sulfonamides is described. The process exhibits significant functional group tolerance and allows for the preparation of a number of arylsulfonyl chlorides and sulfonamides under mild conditions.

CHEMICAL COMPOUNDS

The present invention relates generally to novel therapeutic compounds and AXOR 109 agonists, and processes for the manufacture and use of the same.

Thiol sulfonamide metalloprotease inhibitors

This invention is directed to proteinase (protease) inhibitors, and more particularly to thiol sulfonamide inhibitors for matrix metalloproteinase 13(MMP-13), compositions of proteinase inhibitors, intermediates for the syntheses of proteinase inhibitors, processes for the preparation of proteinase inhibitors and processes for treating pathological conditions associated with pathological matrix metalloproteinase activity related to MMP-13.

Preparation of aminoepoxides from aminoaldehydes and an in situ formed halomethyl organometallic reagent

In a method of preparing an aminoepoxide wherein a protected aminoaldehyde is reacted with a halomethyl organometallic reagent in an appropriate solvent at a temperature above -80 DEG C., wherein said halomethyl organometallic reagent is formed by reaction between an organometallic reagent and a dihalomethane, the improvement comprising flowing said protected aminoaldehyde into a mixing zone maintained at a temperature below 0 DEG C., also flowing said halomethyl organometallic reagent in said mixing zone for contacting in said mixing zone with said protected aminoaldehyde and also withdrawing from said mixing zone reaction products of said protected aminoaldehyde and said halomethyl organometallic reagent.

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Benzene sulfonamides as PDE-V inhibitors for the use against erectile dysfunction

The compounds of formula (I) wherein X, R0, R1, R2, n and m have the meanings given in the specification, are useful as active ingredients in pharmaceutical compositions. The invention relates to the use of said compounds as a medicament and for the manufacture of a medicament for the treatment of erectile dysfunction.

Sulfonamide inhibitors of aspartyl protease

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.